Skip to main content
logo
Eupraxia Pharmaceuticals Inc. (EPRX)
NASDAQ: EPRX · Real-Time Price · USD
6.10
+0.29 (4.99%)
Jul 27, 2026, 9:41 AM EDT - Market open

Eupraxia Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
18.6117.110.927.483.996.48
Research & Development
28.6621.3316.0820.3613.637.58
Operating Expenses
47.2738.432727.8517.6214.15
Operating Income
-47.27-38.43-27-27.85-17.62-14.15
Interest Expense
---0.96-1.17-0.98-0.97
Interest & Investment Income
2.181.411.160.860.430.05
Currency Exchange Gain (Loss)
0.63-1.56-0.160.070.240.16
Other Non Operating Income (Expenses)
--1.2-0.84-1.06-4.74
EBT Excluding Unusual Items
-44.46-38.58-25.76-28.92-18.98-19.65
Gain (Loss) on Sale of Assets
-0-00.02-0-0.01-
Other Unusual Items
-----0.42
Pretax Income
-44.46-38.59-25.74-28.93-18.99-19.23
Income Tax Expense
0.030.0200.04--
Earnings From Continuing Operations
-44.49-38.61-25.74-28.97-18.99-19.23
Minority Interest in Earnings
0.030.030.240.750.50.3
Net Income
-44.47-38.58-25.5-28.22-18.49-18.93
Preferred Dividends & Other Adjustments
2.512.530.43---
Net Income to Common
-46.98-41.11-25.93-28.22-18.49-18.93
Net Income Growth
------
Shares Outstanding (Basic)
454034241912
Shares Outstanding (Diluted)
454034241912
Shares Change
26.83%17.76%40.52%25.21%55.45%102.75%
EPS (Basic)
-1.04-1.03-0.76-1.17-0.96-1.53
EPS (Diluted)
-1.04-1.03-0.76-1.17-0.96-1.53
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-33.44-29.14-30.1-20.82-14.63-12.06
Free Cash Flow Per Share
-0.74-0.73-0.89-0.86-0.76-0.97
EBITDA
-47.07-38.27-26.89-27.73-17.51-14.11
D&A For EBITDA
0.20.160.110.110.110.04
EBIT
-47.27-38.43-27-27.85-17.62-14.15
SEC Filings: 10-K · 10-Q